^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Duoenda (mitoxantrone liposomal)

    i
    Other names: PLM60, 2010L04017, HE071
    Associations

    News

    Trials
    Company:
    CSPC Pharma
    Drug class:
    Topoisomerase II inhibitor, DNA intercalator
    Related drugs:
    Associations

    News

    Trials
    1m
    A prospective multicenter randomized controlled clinical study comparing the efficacy and safety of mitoxantrone hydrochloride liposomes with idarubicin in induction therapy for children with newly diagnosed acute myelocytic leukemia (ChiCTR2500111195)
    P=N/A, N=220, Not yet recruiting, The First Affiliated Hospital,Sun Yat-sen University; The First Affiliated Hospital,Sun Yat-sen University
    New trial
    |
    Venclexta (venetoclax) • idarubicin hydrochloride • Duoenda (mitoxantrone liposomal)
    1m
    Study on the Efficacy and Safety of Mitoxantrone Liposome-Containing Regimens in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia in the Real World (ChiCTR2500111194)
    P4, N=60, Recruiting, Tongji Hospital Affiliated to Tongji Medical College Huazhong University of Science and Technology; Tongji Hospital Affiliated to Tongji Medical Colle
    New P4 trial • Real-world evidence
    |
    Venclexta (venetoclax) • azacitidine • Duoenda (mitoxantrone liposomal)
    1m
    A Prospective, Multicenter, Randomized Controlled, Phase II Clinical Study of Venetoclax and Azacitidine Combined with Mitoxantrone Hydrochloride Liposome Injection Versus Intensive Chemotherapy in the Treatment of Newly Diagnosed Intermediate- to High-Risk fit AML (ChiCTR2500109764)
    P4, N=198, Not yet recruiting, Tangdu Hospital, Fourth Military Medical University; Tangdu Hospital, Fourth Military Medical University
    New P4 trial
    |
    Venclexta (venetoclax) • azacitidine • Duoenda (mitoxantrone liposomal)
    1m
    A multicenter, single-arm, phase II clinical study of mitoxantrone hydrochloride liposome injection combined with azacitidine and venetoclax in the treatment of relapsed/refractory acute myeloid leukemia after standard induction therapy (ChiCTR2500109729)
    P4, N=38, Not yet recruiting, The First Affiliated Hospital of Army Medical University; The First Affiliated Hospital of Army Medical University
    New P4 trial
    |
    Venclexta (venetoclax) • azacitidine • Duoenda (mitoxantrone liposomal)
    1m
    A multicenter, single-arm, phase II clinical study of mitoxantrone hydrochloride liposome injection combined with azacitidine and venetoclax in the treatment of venetoclax-exposed refractory/relapsed acute myeloid leukemia (ChiCTR2500109360)
    P4, N=30, Not yet recruiting, The First Affiliated Hospital of Army Medical University; The First Affiliated Hospital of Army Medical University
    New P4 trial
    |
    Venclexta (venetoclax) • azacitidine • Duoenda (mitoxantrone liposomal)
    1m
    Phase II Study Evaluating the Combination of Linperlisib, Azacitidine, and Liposomal Mitoxantrone in Treatment-Naïve Nodal TFH Cell Lymphoma (ChiCTR2500107944)
    P2, N=30, Not yet recruiting, The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University
    New P2 trial
    |
    azacitidine • Zepsun (donafenib) • Itari (linperlisib) • Duoenda (mitoxantrone liposomal)
    3ms
    Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML (clinicaltrials.gov)
    P2, N=72, Recruiting, First Affiliated Hospital of Zhejiang University | Phase classification: P=N/A --> P2 | N=20 --> 72 | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • Duoenda (mitoxantrone liposomal)
    3ms
    Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITL (clinicaltrials.gov)
    P2, N=40, Recruiting, The Affiliated Hospital of Xuzhou Medical University
    New P2 trial
    |
    Tevimbra (tislelizumab-jsgr) • cyclophosphamide • prednisone • Epidaza (chidamide) • Duoenda (mitoxantrone liposomal)
    3ms
    Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL) (clinicaltrials.gov)
    P1, N=16, Enrolling by invitation, BGI, China | Recruiting --> Enrolling by invitation
    Enrollment status
    |
    cyclophosphamide • decitabine • Duoenda (mitoxantrone liposomal)
    4ms
    A Single-Arm, Prospective Clinical Study of Venetoclax Combined with Fludarabine, Liposomal Mitoxantrone, and Dexamethasone (FMD Regimen) for the Treatment of Multiple Myeloma with Secondary Extramedullary Disease (ChiCTR2500107131)
    P3, N=20, Recruiting, The First Affiliated Hospital of Zhejiang Chinese Medical University; The First Affiliated Hospital of Zhejiang Chinese Medical University
    New P3 trial
    |
    Venclexta (venetoclax) • fludarabine IV • Duoenda (mitoxantrone liposomal)
    4ms
    Venetoclax combined with half-dose CMG regimen (cytarabine, mitoxantrone liposomes, and granulocyte colony-stimulating factor) for the treatment of newly diagnosed patients who are intolerant to intensive chemotherapy Single-center, exploratory clinical study on acute myeloid leukemia (ChiCTR2500105011)
    P=N/A, N=20, Recruiting, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine; Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of
    New trial
    |
    Venclexta (venetoclax) • Duoenda (mitoxantrone liposomal)
    4ms
    Clinical study of MEAM regimen for preconditioning autologous hematopoietic stem cell transplantation in lymphoma patients (ChiCTR2500104405)
    P4, N=53, Not yet recruiting, The First Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Xi'an Jiaotong University
    New P4 trial
    |
    cytarabine • etoposide IV • Duoenda (mitoxantrone liposomal)